Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
In subjects with T2DM, Stage 2 or 3 CKD and macroalbuminuria who are receiving standard of care, to assess the efficacy of canagliflozin relative to placebo in reducing the composite endpoint of ESKD, doubling of serum creatinine, and renal or CV death.
Critère d'inclusion
- Type 2 Diabetes Mellitus and Diabetic Nephropathy